Skip to content

Effectiveness of Hypertonic saline in edema in Nephrotic syndrome

Efficacy and safety of hypertonic saline with furosemide in nephrotic syndrome edema: an open-label non-inferiority randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107643
Enrollment
40
Registered
2026-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes

Interventions

Intervention1: Hypertonic saline (3%NS) with furosemide: Hypertonic saline 5ml/kg (max 100ml) infused over 1 hour followed by IV Furosemide 1mg/kg Control Intervention1: Albumin with furosemide: 20% A

Sponsors

Suchitra R
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. 1 to 14 year old with nephrotic syndrome with moderate to severe edema 2. Sodium avidity evidenced by FENa less than 0.5% or urine sodium less than equal to 20mmol/l 3. eGFR more than 60ml/min/1.73m2 4. Serum albumin less than 2g/dl

Exclusion criteria

Exclusion criteria: 1. Secondary forms of nephrotic syndrome 2. Serum sodium more than 145meq/l 3. Clinical hypovolemia, pulmonary edema and congestive cardiac failure 4. Have used diuretics or albumin in the last 24 hours 5.Hypersensitivity to albumin or hypertonic saline 6.Previously included in study

Design outcomes

Primary

MeasureTime frame
Urine output (mL/kg) following administration of the Hypertonic saline plus Furosemide vs. 20% Albumin plus FurosemideTimepoint: 24 hours after administration of study intervention

Secondary

MeasureTime frame
Proportion of patients with adequate diuresis (urine output more than 2 ml/kg/hr) Proportion with treatment failure, defined as urine output less than 0.5ml/kg/hr for 24 hr Percentage of weight loss from baseline. Proportion of patients with significant treatment emergent adverse event requiring cessation of therapy, including moderate to severe dehydration, hypotension, any AKI Change in serum electrolytes (sodium, potassium, magnesium), uric acid, blood glucose, & estimated GFR (modified Schwartz) Natriuresis, in meq/kg/hr. & free water clearance Timepoint: Adequate diuresis 24 hours after administration of study intervention. Treatment failure 24 hours after intervention. Weight loss 24 hours after intervention. Adverse events clinically monitored continuously. Change in electrolytes & GFR at 24 hours after intervention Natriuresis & free water clearance 24 hours after intervention

Countries

India

Contacts

Public ContactSuchitra R

Aiims Mangalagiri

maheshvacharya@aiimsmangalagiri.edu.in7411747661

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026